Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 5/20 | 0.51 |
| ▸ | NAMPT | P43490 | 11/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527626 | 0.88 | NR1H2 (0.45) | AVPR1ANAMPTGPR119 | |
| SCHEMBL25299663 | 0.88 | NR1H2 (0.45) | AVPR1ANAMPTGPR119 | |
| SCHEMBL30623466 | 0.81 | AVPR1A (0.50) | AVPR1AGPR119 | |
| SCHEMBL12701623 | 0.81 | AVPR1A (0.50) | AVPR1AGPR119 | |
| SCHEMBL17586450 | 0.81 | AVPR1A (0.49) | AVPR1AGPR119 | |
| SCHEMBL4069516 | 0.80 | NAMPT (0.50) | AVPR1ANAMPTGPR119 | |
| SCHEMBL4317900 | 0.80 | MCHR1 (0.51) | AVPR1AGPR119 | |
| SCHEMBL4071328 | 0.78 | AVPR1A (0.44) | AVPR1ANAMPTGPR119 | |
| SCHEMBL2755063 | 0.78 | AVPR1A (0.47) | AVPR1A | |
| SCHEMBL4327393 | 0.78 | AVPR1A (0.49) | AVPR1AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | AVPR1A 364/4885NAMPT 3016/4885GPR119 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.